Baby drug dosing study aims to prevent post-surgery breathing problems

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Child, male or female, aged \< 24 months. * American Society of Anesthesiologists (ASA) Physical Status Class I or II. * Non-cardiac and non-emergency surgical procedure, or relative emergency (\>12 h) requiring neuromuscular blockade with rocuronium and reversal with sugammadex. * Surgical procedure allowing neuromuscular monitoring at the adductor pollicis muscle. * Child covered by a social security regiment. * Written informed consent signed by the holder(s) of parental authority. * French-speaking holder(s) of parental authority. Exclusion Criteria: * Child who received or will receive toremifene or fusidic acid within 24 hours before or after administration of the study treatments (rocuronium, sugammadex). * Use of two different neuromuscular blocking agents during the procedure. * Failure to calibrate the Train-of-Four (TOF) qualitative count (TOFc) and quantitative ratio (TOFr). * Non-compliance with the titrated administration protocol of sugammadex and TOF monitoring during the study. * Use, during the procedure, of medications that may interfere with the study treatments: aminoglycosides, lincosamides, polymyxins, quinidine, quinine, magnesium salts, phenytoin, carbamazepine, or continuous IV lidocaine. Non inclusions criteria : * Emergency requiring care in the operating room within \< 12 hours. * Child weighing more than 20 kg. * Premature child: \< 37 weeks gestational age at birth. * Suspected or diagnosed neuromuscular disorder at the time of surgical care. * Child suspected of having,or with a family history of, malignant hyperthermia. * Child suspected of having, or with a known allergy to, the medications used in the study (rocuronium, sugammadex) or any of their respective excipients. * Child expected to require mechanical ventilation at the end of the surgical procedure. * Child receiving, at the time of inclusion, regular treatment with medications that may interfere with the treatments used in this study: aminoglycosides, lincosamides, polymyxins, quinidine, quinine, magnesium salts, phenytoin, carbamazepine. * Minor holders of parental authority, or children under guardianship or curatorship.